💸 The Tape

Curaleaf (TSX: CURA) filed an application with the Alberta Securities Commission Monday asking it to shut down Aurora Cannabis's at-the-market equity program for as long as Curaleaf's US$4.00-per-share hostile bid remains open. It wants an expedited hearing, and it wants the ASC to declare Aurora's share sales an "improper and abusive defensive tactic."

The numbers in the filing are specific. Since Curaleaf first approached Aurora in June, Aurora has sold roughly 2.81 million shares at an average of US$3.04 through the ATM. That's about 4.9% dilution over the summer and 10.8% since the program launched in February — and, by Curaleaf's math, more than US$11 million added to the cost of buying the whole company. Curaleaf notes the program was launched with a promise that proceeds would go to "strategic and accretive purposes only," and that Aurora has spent the last month describing itself as debt-free with C$149 million of cash.

Boris Jordan's quote does the rest of the work: if US$4.00 is too cheap and the balance sheet is fine, why is management selling stock at US$3.04?

Why this is the right question

Strip away the hostile-bid theatre and the ATM issue is the single most legible fact in this entire fight. Valuation arguments are debatable — sum-of-the-parts versus forward EBITDA, cash-adjusted premiums versus intrinsic value. Reasonable people can pick a side. But there is no valuation framework in which a board can tell shareholders that US$4.00 "significantly undervalues" the company while simultaneously issuing shares to the market at 24% below that number. The board is either wrong about fair value or wrong to be selling. It cannot be right about both.

That contradiction is why Curaleaf keeps returning to it. It has already made the ATM the centerpiece of its September 2 rebuttal and its September 8 "myth versus fact" sheet. Taking it to the ASC escalates it from talking point to legal claim, and Canadian securities regulators have a long-standing policy — National Policy 62-202 — that defensive tactics are acceptable only if they don't deny shareholders the ability to respond to a bid. An ATM isn't a poison pill, and 2.8 million shares is small money. But a regulator being asked "is the target using its own share count to make an offer harder to complete?" is a question the target would rather not answer under oath.

Games, or just bad optics?

Here's the fair version. Aurora's ATM predates the bid by four months. Companies with ATMs sell into liquidity; that's what the program is for. Aurora may have had capex commitments, working capital timing, or simply an autopilot broker order that nobody paused. There's a defensible, boring explanation.

Here's the problem with it. Curaleaf says Aurora knew of its interest in June. Aurora kept selling. Curaleaf announced its intention to bid in early August. Aurora kept selling. Aurora's board issued a directors' circular on September 1 calling the offer inadequate — and the ATM was, apparently, still running. At some point "we didn't think to stop it" becomes "we chose not to," and the second version is much harder to defend in front of a regulator.

The bigger tell is what Aurora hasn't done. In five weeks it has not named a counter-price, not announced a strategic review, not signed a confidentiality agreement, not floated a buyback or special dividend, and not said a public word since September 1 beyond "no further comment." A management team that believed its own sum-of-the-parts math would be shouting it. Instead the record shows a board rejecting a bid without testing for a higher one, while the company quietly sold shares below it. That isn't necessarily amateur hour, but it's the kind of process gap that proxy advisors and special committees exist to prevent, and Curaleaf is making sure ISS and Glass Lewis see it.

Where this goes from here

The calendar now has several moving parts, and they interact.

Weeks, not months, on the ASC. Curaleaf asked for an expedited hearing. Expect Aurora to respond within days and a hearing in late September or early October. The likeliest outcomes are a cease-trade of the ATM during the bid or a voluntary suspension by Aurora to avoid a ruling. Either way, the ATM is probably done. The real prize for Curaleaf isn't the shares — it's the finding, or the concession, that the sales were a defensive tactic.

Early November: Aurora's fiscal Q2. This is Aurora's last chance to change the narrative with numbers. Management guided fiscal 2027 lower; if international medical accelerates and margins stabilize, the "declining business" framing weakens. If EBITDA prints another single-digit quarter, the board's inadequacy opinion becomes untenable.

December 1: the bid expires. Canadian takeover rules set a 105-day minimum deposit period, which Aurora's board can shorten to 35 days if it wants to force the issue — an option Curaleaf keeps pointing out. The bid needs more than 50% of shares not already held by Curaleaf to be tendered; if that threshold is met, it extends ten days to let holdouts in. With Aurora trading around US$3.70, the market is saying the bid gets done or improved, not that it fails.

The bump. Every Curaleaf release since August has ended with an invitation to talk price. That's a bidder with room. The realistic sequence is: ASC resolves the ATM, Aurora reports Q2, a second bidder either surfaces or doesn't, and Curaleaf raises to somewhere between US$4.50 and US$5.50 with a larger cash component in mid-November to secure a board recommendation ahead of expiry. If Aurora's board still refuses, the December 1 tender count decides it, and a board that lost the tender loses the boardroom.

The wildcard is rescheduling. If the DEA administrator moves adult-use cannabis to Schedule III before December, Curaleaf's stock re-rates, the US$5.00 cap becomes the operative price, and Aurora's "capped upside" argument evaporates.

The ATM filing won't decide the deal. But it decides who's on defense — and right now that's Aurora, explaining to a regulator why it sold shares it claimed were worth more.

📈 Dog Walkers

$VFF ( ▲ 0.7% ) Makes New Hire

Village Farms (NASDAQ: VFF) has created a new seat at the leadership table and filled it with a name nearly everyone in Canadian cannabis knows. Deepak Anand joins as Vice President of Government Affairs, reporting to Chief Strategy Officer Brian Stevenson, with a brief that covers government relations, regulatory affairs and public policy across the company's entire global footprint.

The résumé explains the hire. Anand spent the last several years running ASDA Consultancy Services, advising more than 40 cannabis companies plus tobacco and CPG players looking for a way into the plant. Before that he was VP of Government Relations at Cannabis Compliance Inc., the regulatory shop Deloitte eventually bought, and VP of Business Development at Zenabis. He's built businesses in Germany and the UK, sat on the Valens board, and has spent close to two decades in rooms with regulators on three continents. If there's a cannabis policy conversation happening in Ottawa, Berlin or Canberra, he's usually been in it.

CEO Michael DeGiglio framed the appointment as a signal that international government affairs is now a strategic function, not a compliance afterthought. That tracks with where Village Farms is pointed: the world's largest EU-GMP facility in Delta, one of ten licences in the Dutch regulated program, equity stakes in Australia and Germany, and a CBDistillery brand in the U.S. that will need to navigate the hemp definition change in November. Every one of those markets is moving, and the next round of value — Germany's pharmacy channel, the Netherlands' expansion, Australia's prescriber rules — gets decided in policy rooms before it shows up in revenue.

It's also the second leadership move in a week, following Hamid Shekarchi's promotion to interim CFO. A company that's spent three years proving it can be profitable in Canada is now staffing up to be influential abroad. Anand is the right hire for that job.

📺 Trade To Black

Michigan Governor's Race Turns on Cannabis Tax | TDR Cannabis in 5

• Cannabis money is flowing to James: Republican John James pledged to repeal or slash Michigan's 24% wholesale tax, and a JARS Cannabis fundraiser netted him nearly $90,000 of the $1.2 million raised since July.

• The tax is badly missing projections: Sold as a $420 million-a-year road-funding measure, it collected just $73.4 million in its first six months.

• Benson is hedging: The Democratic nominee calls it a "new and emerging issue" and wants more data before taking a position.

• A test case for thin-margin markets: James has flipped from opposing legalization in 2018 to defending the legal market, and Michigan's saturated pricing means this vote could decide whether consumers stay legal or go illicit.